Copyright
©The Author(s) 2024.
World J Clin Cases. Apr 26, 2024; 12(12): 2056-2064
Published online Apr 26, 2024. doi: 10.12998/wjcc.v12.i12.2056
Published online Apr 26, 2024. doi: 10.12998/wjcc.v12.i12.2056
Ref. | Sample size | Mean age | Subtype | t1 | t2 | t3 | DMARDs (%) | Biologic agents (%) | CS (%) | Treatment duration (wk) | ||||
t1 | t2 | t3 | t1 | t2 | t3 | |||||||||
Ruperto et al[17], 2005 | 73 | 74 | 78 | 8.9 | 9.0 | 7.5 | pJIA, oJIA | Meloxicam (0.125 qd) | Meloxicam (0.250 qd) | Naproxen (5.000 mg/kg) | 24.7/28.4/37.2 | NS | 19.3/22.0/14.9 | 12 |
Foeldvari et al[18], 2009 | 77 | 82 | 83 | 10.4 | 10.2 | 10.4 | pJIA, oJIA | Celecoxib (3.0 mg/kg bid) | Celecoxib (6.0 mg/kg bid) | Naproxen (7.5 mg/kg) | 50.6/47.6/51.8 | 0/3.7/3.6 | NS | 12 |
García-Morteo et al[19], 1987 | 12 | 14 | 8.5 | 8.5 | pJIA, oJIA | Piroxicam | Naproxen (12.5 mg/kg/d) | NS | NS | 11.5 | 12 | |||
Giannini et al[20], 1990 | 45 | 47 | 7.7 | 7.7 | pJIA, oJIA, sJIA | Inuprofen (30-40 mg/kg/d) | Aspirin (60-80 mg/kg/d) | 0 | 0 | NS | 12 | |||
Haapasaari et al[21], 1983 | 15 | 15 | 15 | NS | NS | NS | pJIA, oJIA, sJIA | Diclofenac (2-3 mg/kg/d) | Aspirin (50-100 mg/kg/d) | Placebo | NS | NS | NS | 2 |
Kvien et al[22], 1984 | 40 | 40 | 11.4 | 9.0 | pJIA, oJIA | Naproxen (10 mg/kg/d) | Aspirin (75 mg/kg/d) | 0 | 0 | 0 | 24 | |||
Levinson et al[23], 1977 | 53 | 54 | 9.4 | 9.0 | pJIA, oJIA, sJIA | Tolmetin (15 mg/kg/d) | Aspirin (55 mg/kg/d) | NS | 0 | 0 | 12 | |||
Reiff et al[24], 2006 | 109 | 100 | 101 | 9.7 | 9.4 | 10.7 | pJIA, oJIA | Rofecoxib (0.3 mg/kg qd) | Rofecoxib (0.6 mg/kg) | Naproxen (7.5 mg/kg/d) | 53.2/51.0/45.5 | NS | 19.3/22.0/14.9 | 12 |
- Citation: Zeng T, Ye JZ, Qin H, Xu QQ. Systematic review and network meta-analysis of different non-steroidal anti-inflammatory drugs for juvenile idiopathic arthritis. World J Clin Cases 2024; 12(12): 2056-2064
- URL: https://www.wjgnet.com/2307-8960/full/v12/i12/2056.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i12.2056